Logo image of PXMD

PAXMEDICA INC (PXMD) Stock Fundamental Analysis

USA - NASDAQ:PXMD - US70424C2035 - Common Stock

0.6883 USD
-0.06 (-7.61%)
Last: 5/1/2024, 8:18:16 PM
0.37 USD
-0.32 (-46.24%)
After Hours: 5/1/2024, 8:18:16 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to PXMD. PXMD was compared to 191 industry peers in the Pharmaceuticals industry. While PXMD seems to be doing ok healthwise, there are quite some concerns on its profitability. PXMD is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year PXMD has reported negative net income.
PXMD had a negative operating cash flow in the past year.
In the past 5 years PXMD always reported negative net income.
In the past 5 years PXMD always reported negative operating cash flow.
PXMD Yearly Net Income VS EBIT VS OCF VS FCFPXMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 -5M -10M -15M

1.2 Ratios

Looking at the Return On Assets, with a value of -321.98%, PXMD is doing worse than 94.39% of the companies in the same industry.
The Return On Equity of PXMD (-540.30%) is worse than 83.16% of its industry peers.
Industry RankSector Rank
ROA -321.98%
ROE -540.3%
ROIC N/A
ROA(3y)-856.18%
ROA(5y)-1309.78%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PXMD Yearly ROA, ROE, ROICPXMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 0 0 0 0 0 0 0 0 0 0 0

1.3 Margins

PXMD does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PXMD Yearly Profit, Operating, Gross MarginsPXMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023

More info and screens

6

2. Health

2.1 Basic Checks

The number of shares outstanding for PXMD has been increased compared to 1 year ago.
Compared to 5 years ago, PXMD has more shares outstanding
PXMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
PXMD Yearly Shares OutstandingPXMD Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2M 4M 6M
PXMD Yearly Total Debt VS Total AssetsPXMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 1M 2M 3M 4M 5M

2.2 Solvency

PXMD has an Altman-Z score of -20.05. This is a bad value and indicates that PXMD is not financially healthy and even has some risk of bankruptcy.
PXMD's Altman-Z score of -20.05 is on the low side compared to the rest of the industry. PXMD is outperformed by 86.22% of its industry peers.
PXMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -20.05
ROIC/WACCN/A
WACCN/A
PXMD Yearly LT Debt VS Equity VS FCFPXMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 -5M -10M

2.3 Liquidity

PXMD has a Current Ratio of 3.16. This indicates that PXMD is financially healthy and has no problem in meeting its short term obligations.
PXMD has a Current ratio (3.16) which is comparable to the rest of the industry.
A Quick Ratio of 3.16 indicates that PXMD has no problem at all paying its short term obligations.
PXMD has a Quick ratio (3.16) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.16
Quick Ratio 3.16
PXMD Yearly Current Assets VS Current LiabilitesPXMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M

More info and screens

0

3. Growth

3.1 Past

PXMD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 23.95%, which is quite impressive.
EPS 1Y (TTM)23.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%79.11%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y88.34%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PXMD Yearly EPS VS EstimatesPXMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 -2 -4 -6 -8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

PXMD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PXMD. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PXMD Price Earnings VS Forward Price EarningsPXMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PXMD Per share dataPXMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

PXMD does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PAXMEDICA INC

NASDAQ:PXMD (5/1/2024, 8:18:16 PM)

After market: 0.37 -0.32 (-46.24%)

0.6883

-0.06 (-7.61%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-11 2024-03-11/amc
Earnings (Next)05-13 2024-05-13
Inst Owners0%
Inst Owner Change0%
Ins Owners100.3%
Ins Owner Change0%
Market Cap5.10M
Revenue(TTM)N/A
Net Income(TTM)-18289690
AnalystsN/A
Price Target3.06 (344.57%)
Short Float %0.01%
Short Ratio0
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.51
P/tB 1.51
EV/EBITDA N/A
EPS(TTM)-15.85
EYN/A
EPS(NY)-1.11
Fwd EYN/A
FCF(TTM)-1.45
FCFYN/A
OCF(TTM)-1.45
OCFYN/A
SpS0
BVpS0.46
TBVpS0.46
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -321.98%
ROE -540.3%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-856.18%
ROA(5y)-1309.78%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.16
Quick Ratio 3.16
Altman-Z -20.05
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)23.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%79.11%
EPS Next Y88.34%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-52.13%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-77.41%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-77.41%
OCF growth 3YN/A
OCF growth 5YN/A

PAXMEDICA INC / PXMD FAQ

What is the ChartMill fundamental rating of PAXMEDICA INC (PXMD) stock?

ChartMill assigns a fundamental rating of 2 / 10 to PXMD.


What is the valuation status of PAXMEDICA INC (PXMD) stock?

ChartMill assigns a valuation rating of 0 / 10 to PAXMEDICA INC (PXMD). This can be considered as Overvalued.


What is the profitability of PXMD stock?

PAXMEDICA INC (PXMD) has a profitability rating of 0 / 10.


How financially healthy is PAXMEDICA INC?

The financial health rating of PAXMEDICA INC (PXMD) is 6 / 10.


What is the earnings growth outlook for PAXMEDICA INC?

The Earnings per Share (EPS) of PAXMEDICA INC (PXMD) is expected to grow by 88.34% in the next year.